Adaptogens Explained: The Science, the Markers, the Standardisation

The word “adaptogen” describes a functional concept: a botanical that is traditionally used to help the body resist and adapt to non-specific stress. It is a useful organising idea and a poor specification. No marker compound is shared across the category, the term is not a regulated claim in most markets, and the botanicals grouped under it are chemically unrelated. For a formulator, “adaptogen” is the start of a sourcing question, never the answer to one. The answer lives in the named marker compound, the assay method, and the standardisation behind the number on the certificate of analysis.

What “adaptogen” actually means

The concept was formalised in the mid-twentieth century by Soviet pharmacologists Nikolai Lazarev and Israel Brekhman, who proposed three defining criteria: a substance should be broadly safe and cause minimal disruption to normal physiology; it should produce a non-specific increase in resistance to physical, chemical and biological stressors; and it should have a normalising effect, tending to return an over- or under-active system toward balance regardless of the direction of the deviation. That last property — bidirectional normalisation — is what distinguishes the classical adaptogen idea from a simple stimulant.

These criteria are pharmacological hypotheses with a substantial research literature behind several of the botanicals, not a settled mechanistic definition. The category overlaps with much older traditions — the Ayurvedic concept of rasayana (rejuvenation) and the Traditional Chinese Medicine framing of qi tonics — which is why ashwagandha, holy basil, ginseng and schisandra appear across all three vocabularies under different rationales.

Regulatory status: a category, not a claim

This is the point that most affects how you may use the word commercially. In most major markets “adaptogen” is not an approved health claim. It is a descriptor of a category, not a permitted statement about what a product does to the body.

• European Union — there is no authorised health claim for “adaptogen” or for adaptogenic activity under the EU Nutrition and Health Claims Regulation; the botanical health-claim list itself remains largely on hold. The term cannot be used to imply a specific physiological benefit on a label.
• United States — “adaptogen” is not an FDA-recognised claim; under DSHEA a supplement may carry structure/function statements only with the mandated disclaimer, and these statements may not claim to diagnose, treat, cure or prevent disease.
• General principle — because the word carries no agreed regulatory meaning, it is best treated as trade/educational language describing the botanical category, kept well clear of implied medicinal effect. Frame botanicals as “traditionally used” or “marketed for” a role, and let the marker specification, not the adjective, do the commercial work.

The principle: there is no shared marker

The single most important technical fact about adaptogens is that they share a concept, not a chemistry. Ashwagandha is standardised to steroidal lactones; rhodiola to a phenylpropanoid glycoside and a phenylethanoid; ginseng to triterpene saponins; schisandra to lignans. These are entirely different compound classes, measured by different methods, against different reference standards. A specification that says only “standardised adaptogen extract” without naming the marker compound and its percentage tells you nothing testable. Everything that follows is botanical-by-botanical for exactly this reason.

Ashwagandha — withanolides

Ashwagandha (Withania somnifera), a cornerstone rasayana botanical from Ayurveda, is traditionally used as a calming tonic and is the most commercially significant adaptogen by volume. Its characteristic markers are the withanolides — a family of C28 steroidal lactones — typically quantified as total withanolides, with withaferin A and the withanolide glycosides (withanosides) of particular analytical interest.

Standardisation is usually expressed as a percentage of total withanolides, commonly in the 1.5%–5% range for root extracts, measured by HPLC against withanolide reference standards. A formulator should confirm two things in particular: that the marker is total withanolides determined by HPLC (not a non-specific gravimetric or spectrophotometric figure that can be inflated by unrelated material), and that the extract is root-derived where the specification or tradition calls for root, since leaf material carries a different withanolide profile and higher withaferin A. Branded, clinically referenced ashwagandha extracts typically publish a defined withanolide range and the part of the plant used.

Rhodiola — rosavins and salidroside

Rhodiola (Rhodiola rosea), an Arctic and alpine root traditionally used to counter fatigue, is standardised to two distinct markers that must both be reported: the rosavins (a group comprising rosavin, rosarin and rosin) and salidroside (a phenylethanoid glycoside, also called rhodioloside). The widely used benchmark is a defined ratio — frequently around 3:1 rosavins to salidroside — which mirrors the proportions found in authentic R. rosea root.

That ratio is not a marketing flourish; it is an authenticity control. Rosavins are characteristic of R. rosea specifically, whereas salidroside occurs in several Rhodiola species. An extract standardised to salidroside alone, with little or no rosavin, is a flag for substitution with a cheaper Rhodiola species (R. crenulata is the common adulterant). Specify both markers, the ratio, and HPLC quantification, and treat a missing rosavin figure as an open question about species identity.

Eleuthero — eleutherosides

Eleuthero (Eleutherococcus senticosus), historically marketed as “Siberian ginseng” though botanically unrelated to true Panax ginseng, is standardised to the eleutherosides — a chemically heterogeneous group whose principal analytical markers are eleutheroside B (a phenylpropanoid, syringin) and eleutheroside E (a lignan). Total eleutherosides B and E, determined by HPLC, is the usual specification, often in the region of 0.8% and upward depending on grade.

Two cautions matter here. First, “Siberian ginseng” is a legacy trade name that is restricted or discouraged in several markets precisely because it implies a relationship to Panax that does not exist; use the botanical name Eleutherococcus senticosus. Second, because the eleutherosides are structurally diverse, confirm that the assay measures defined, named eleutherosides (B and E) rather than a generic total — the named-marker approach is what makes the figure comparable lot to lot.

Schisandra — schisandrins (lignans)

Schisandra (Schisandra chinensis), the “five-flavour berry” of Traditional Chinese Medicine, is standardised to its dibenzocyclooctadiene lignans, often reported as total schisandrins or against schisandrin (schizandrin) and schisandrin B (γ-schisandrin) as named markers. HPLC quantification against lignan reference standards is the norm, with specifications commonly expressed as a percentage of total schisandra lignans.

The practical point for buyers is reference-standard discipline. The schisandra lignan family is large and the nomenclature is inconsistent across suppliers (schisandrin, schizandrin, deoxyschisandrin, schisandrin A/B/C and gomisins all appear). Pin down exactly which lignans the percentage refers to and against which standard they were measured, or two “2% lignan” extracts will not be comparable.

Holy basil, Panax ginseng & cordyceps

Three further botanicals round out the working list, each with its own marker logic.

Holy basil (Tulsi)

Holy basil (Ocimum sanctum, syn. Ocimum tenuiflorum), a revered Ayurvedic rasayana, is most often standardised to ursolic acid (a triterpenoid) and characterised by its volatile-oil constituents, principally eugenol. Ursolic acid by HPLC is the common quantitative marker; eugenol content, determined by gas chromatography (GC), characterises the essential-oil fraction. Specify which marker governs the lot, as a leaf-powder, a hydroethanolic extract and an essential oil are very different materials sold under the same common name.

Panax ginseng

Panax ginseng (Asian/Korean ginseng) — the original qi tonic — is standardised to ginsenosides, a large family of triterpene saponins reported as total ginsenosides and against named individual ginsenosides (Rg1, Rb1, Rg3 and others) by HPLC. Note the species distinction that the trade routinely blurs: Panax ginseng, Panax quinquefolius (American ginseng) and Panax notoginseng have different ginsenoside profiles and are not interchangeable, and neither is eleuthero, despite the “ginseng” label. Require the Panax species name alongside the ginsenoside figure.

Cordyceps

Cordyceps (traditionally Cordyceps sinensis, now Ophiocordyceps sinensis; most commercial material is the cultivated species Cordyceps militaris or the mycelial strain Cs-4) is commonly standardised to cordycepin and/or adenosine as nucleoside markers, and separately to polysaccharides (often reported as beta-glucans) by an enzymatic assay rather than the colourimetric methods that overstate glucan content. For fungal materials, also confirm whether the product is fruiting body or mycelium-on-grain, since the latter can dilute true beta-glucans with residual starch.

Botanical → marker → method, at a glance

The table consolidates the working markers and their typical analytical methods. Read it as a specification checklist: for any adaptogen you source, the COA should name a compound from the marker column, a percentage, and a method from the method column — not the word “adaptogen” alone.

How an adaptogen is standardised and tested

Across the category the standardisation workflow is the same shape, even though the chemistry differs. Knowing the shape lets you interrogate any adaptogen COA with the same set of questions.

1. 1Identity first — confirm the species by botanical authentication (macroscopic/microscopic, and increasingly DNA-based or HPTLC fingerprinting) before any potency figure means anything; the marker confirms identity only once the species is verified.
2. 2Marker selection — fix the named marker compound(s) for the botanical (withanolides, rosavins + salidroside, ginsenosides, and so on), not a generic “total extractives” figure.
3. 3Quantification — measure the marker by a specific, validated method, predominantly HPLC for non-volatile markers and GC for volatile constituents such as eugenol; enzymatic assays for fungal beta-glucans.
4. 4Reference standards — quantify against characterised reference standards for the exact compounds named, so percentages are comparable between lots and suppliers.
5. 5Ratio / profile checks — where a species-identity ratio exists (e.g. rosavins:salidroside), verify it as an adulteration guard, not just a potency check.
6. 6Contaminant and safety panel — pair the potency assay with heavy metals, pesticide residues, microbiology and (for the relevant botanicals) solvent residues, since standardisation governs efficacy but not safety.

What a formulator should look for

Reduced to the essentials, a sound adaptogen specification answers a short list of questions. If any are unanswered, the “adaptogen” label is doing work that the data should be doing.

• Named marker, named percentage — exactly which compound(s) the standardisation refers to, and the target range, not just “standardised extract.”
• Method and reference standard — HPLC or GC (as appropriate), validated, against characterised standards for the named markers.
• Species and plant part — full botanical name and the part used (root, aerial, berry, fruiting body), with authentication evidence behind it.
• Authenticity / ratio controls — the species-distinguishing marker where adulteration is a known risk (rosavins for rhodiola, Panax species for ginseng, fruiting body for cordyceps).
• Extract ratio and carrier — the native-to-finished ratio and any carrier (e.g. maltodextrin), so the marker percentage is read in context.
• Full safety panel — heavy metals, pesticides, microbiology and residual solvents to the relevant market limits.
• Clinical/dossier alignment — where a branded extract is referenced for a marketed role, confirm the lot matches the characterised material the evidence was generated on.

Claim and compliance cautions

Because the category sits in a regulatory grey zone, the commercial risk on adaptogens is rarely the chemistry and usually the language. A few disciplines keep the work defensible.

• Describe traditional use, not effect — “traditionally used in Ayurveda” or “marketed for” a role is defensible; an implied physiological or disease benefit is a regulatory claim that “adaptogen” does not license.
• Keep the marker, drop the adjective on-label — specify and sell on the named marker and content; route any benefit language through market-specific regulatory review.
• Mind legacy names — avoid “Siberian ginseng” for eleuthero and do not let the “ginseng” common name imply Panax equivalence.
• Match claim to dossier — if you reference a branded extract’s research, your finished product and dose must align with the characterised material, or the reference does not transfer.
• Standardisation is not a safety statement — a high marker percentage says nothing about contaminants; the safety panel is a separate, non-negotiable requirement.